The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 8, 2014, Pages 1211-1216

  Donato, Michele L ^a   Siegel, David S ^a   Vesole, David H ^a   McKiernan, Phyllis ^a   Nyirenda, Themba ^a   Pecora, Andrew L ^a   Baker, Melissa ^a   Goldberg, Stuart L ^a   Mato, Anthony ^a   Goy, Andre ^a   Rowley, Scott D ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Allogeneic; Graft versus host disease; Multiple myeloma; Transplantation

Indexed keywords

BUSULFAN; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOGRAFT; AUTOTRANSPLANTATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS MYELOMA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SIBLING; TREATMENT RESPONSE; UNRELATED DONORS; ALLOTRANSPLANTATION; CHRONIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84903939750     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.04.027     Document Type: Article

References (31)

1. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. NEngl J Med 2005, 352:2487-2498.
2. Vij R., Wang M., Kaufman J.L., et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood 2012, 119:5661-5670.
3. Palumbo A., Hajek R., Delforge M., et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. NEngl J Med 2012, 366:1759-1769.
4. Richardson P.G., Siegel D., Baz R., et al. Phase I study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013, 121:1961-1967.
5. National Cancer Institute, Surveillance, Epidemiology and End Results Program (SEER) data 2003-2009. Available at: http://seer.cancer.gov/statfacts/html/mulmy.html.
6. McCarthy P.L., Hahn T., Hassebroek A., et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013, 19:1116-1123.
7. Gahrton G., Tura S., Ljiungman P., et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. NEngl J Med 1991, 325:1267-1273.
8. Kumar S., Zhang M.J., Peigang L., et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood 2011, 118:1979-1988.
9. Krishnan A.A., Pasquini M.C., Logan B., et al. Autologous haematopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
10. Gahrton G., Iacobelli S., Bjorkstrang B., et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013, 121:5055-5063.
11. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
12. Small T.N., Young J.W., Castro-Malaspina H., et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant 2007, 13:235-244.
13. Grosskreutz C., Ross V., Scigliano E., et al. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant 2003, 9:453-459.
14. Przepiorka D., Khouri I., Ippoliti C., et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999, 24:763-768.
15. Nieto Y., Patton N., Hawkins T., et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006, 12:217-225.
16. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
17. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institute of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
18. Bruno B., Rotta M., Patriarca F., et al. Acomparison of allografting with autografting for newly diagnosed myeloma. NEngl J Med 2007, 356:1110-1120.
19. Bjorkstrand B., Iacobelli S., Hegenbart U., et al. Tandem autologous/reduced-intensity conditioning transplantation versus autologous transplantation in myeloma: long-term follow-up. JClin Oncol 2011, 269:3016-3022.
20. Ballen K.K., King R., Carston M., et al. Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplant 2005, 35:675-681.
21. Horowitz M.M. Does matched unrelated donor transplantation have thesame outcome as matched sibling transplantation in unselected patients?. Best Pract Res Clin Haematol 2012, 25:483-486.
22. El-Cheikh J., Crocchiolo R., Boher J.M., et al. Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopietic stem cell transplantation in patients with high-risk multiple myeloma. Eur J Haematol 2012, 88:497-503.
23. Efebera Y.A., Qureshi S.R., Cole S.M., et al. Reduced-intensity allogeneichematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 2010, 16:1122-1129.
24. Freyes C.O., Vesole D.H., LeRademacher J., et al. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant 2014, 49:416-421.
25. Hong SH, Siegel D, Donato ML, etal. (ASH Annual Meeting Abstracts) Blood 2012;120: Abstract3104.
26. Crawley C., Lalancette M., Szydlo K., et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005, 105:4532-4539.
27. Paiva B., Gutiérrez N.C., Rosiňol L., et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2011, 119:687-691.
28. Neben K., Jauch A., Bertsch U., et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010, 95:1150-1157.
29. Kröger N., Badbaran A., Zabelina T., et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013, 19:398-404.
30. Passera R., Pollichieni S., Brunello L., et al. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Registry. Biol Blood Marrow Transplant 2013, 19:940-948.
31. Beitinjaneh A.M., Saliba R., Bashir Q., et al. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma 2012, 53:1525-1529.